NCT05742022 is a Phase 2, PHASE3 clinical trial of "Phospholipovit" in Combined Hyperlipidemia, sponsored by Institute of Biomedical Chemistry, Russia.

Who is sponsoring NCT05742022?

NCT05742022 is sponsored by Institute of Biomedical Chemistry, Russia.

What drugs are being tested in NCT05742022?

Interventions in NCT05742022: "Phospholipovit", Placebo.

What condition does NCT05742022 study?

NCT05742022 studies Combined Hyperlipidemia.

Is NCT05742022 still recruiting?

NCT05742022 is currently completed. Last updated 23 February 2023.

Last reviewed 2023-02-23 · How we verify

NCT05742022

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

"Phospholipovit" vs Placebo in Patients With Combined Hyperlipidemia

Completed Phase 2, PHASE3 Last updated 23 February 2023

What this trial tests

Phase 2, PHASE3 trial testing "Phospholipovit" in Combined Hyperlipidemia in 100 participants. Completed in 20 December 2022.

Timeline

1 January 2016

Primary endpoint
20 June 2018

20 December 2022

Quick facts

Lead sponsor	Institute of Biomedical Chemistry, Russia
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	100
Start date	1 January 2016
Primary completion	20 June 2018
Estimated completion	20 December 2022
Sites	3 locations across Russia

Drugs / interventions tested

"Phospholipovit" — full drug profile →
Placebo

Conditions studied

Combined Hyperlipidemia — all drugs for Combined Hyperlipidemia →

Sponsor

Institute of Biomedical Chemistry, Russia

Who can join

Adults 30 to 75, any sex, with Combined Hyperlipidemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

"Phospholipovit" vs placebo in patients with combined hyperlipidemia

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Transepithelial transport of nanoparticles in oral drug delivery: From the perspective of surface and holistic property modulation.
Zheng Y, Luo S, Xu M, He Q, et al · · 2024 · cited 47× · PMID 39309496 · DOI 10.1016/j.apsb.2024.06.015

Verify or expand the search:

Other Institute of Biomedical Chemistry, Russia trials

Trials by the same sponsor.

NCT06177405 — Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05742022 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Biomedical Chemistry, Russia
Last refreshed: 23 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05742022.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing